Back

AbbVie presents 60 dermatology abstracts at 2026 EADV Congress

Verifying
  • AbbVie presented 60 abstracts at the 2026 European Academy of Dermatology and Venereology Congress.
  • Risankizumab and upadacitinib were among the approved drugs featured in AbbVie’s data.
  • AbbVie also showcased investigational programs from its dermatology portfolio.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.